Hutch News Stories | February 16, 2023
Fred Hutch News Service interviews Dr. Hill on the Hill Groups' recent work.
Science Spotlight | December 20, 2021
The December 2021 issue of Fred Hutch's Science Spotlight features a write-up regarding research conducted by Dr. Carla Walti, a Visiting Fellow in the Hill Group.
Cancer Therapy Advisor | December 7, 2021
Dr. Josh Hill speaks with Cancer Therapy Advisor regarding COVID-19 breakthrough infection risks within vaccinated cancer patients.
IDSA | November 16, 2021
Dr. Josh Hill is designtated as a Fellow of IDSA.
MedPage Today | November 2, 2021
Dr. Josh Hill discusses the phase III Remdesivir study results.
ContagionLive | September 30, 2021
In an interview, Dr. Josh Hill discusses what the new data mean for using Remdesivir to reduce COVID-19 burden.
Bloomberg | September 22, 2021
Bloomberg interviews Dr. Josh Hill about research he is presenting at an upcoming late breaker IDWeek 2021 talk.
JAMA | May 5, 2021
Dr. Josh Hill is quoted in this article regarding immunocrompised patients.
businesswire | May 18, 2021
Dr. Josh Hill is the Study Chair for the joint CIBMRT and BMT CTN study.
Healio | March 17, 2021
In Practice interviews Dr. Josh Hill on infection risk during CAR T-cell therapy.
King 5 News | May 14, 2021
King 5 News interviews Dr. Josh Hill on future masking and social distancing needs for people with compromised immunity.
UW Department of Medicine | May 13, 2021
Dr. Joshua Hill is the recipient of the 2021 Fialkow Scholar Award.
The Video Journal of Hematological Oncology | February 10, 2021
VJHEMONC interviews Dr. Josh Hill during the 3rd European CAR T-cell Meeting.
Multiple Myeloma Hub | February 18, 2021
Dr. Josh Hill speaks with the Multiple Myeloma Hub on managing infection risk in patients treated with immunotherapies.
SHARE | February 11, 2021
In this webinar, Dr. Josh Hill answers the most common vaccine related questions and explains the vaccine in relation to cancer patients and their treatment.
Cancer Health | December 24, 2020
Dr. Josh Hill weighs in on vaccines in cancer patients during an American Society of Clinical Oncology (ASCO) expert panel.
Q13 FOX | December 2, 2020
Dr. Josh Hill responds to the recent recommendations from the CDC on new quarantine guidelines.
Medscape | October 13, 2020
In a news story, Dr. Josh Hill discussed treating immune responses in COVID-19 patients.
Science Spotlight | January 2020
From the Hill and Turtle laboratories, Vaccine and Infections Disease Division and Clinical Research Division
Hutch News | Jake Siegel | January 2020
Dr. Josh Hill will study how immunotherapy impacts patients’ ability to fight off bugs.
ASH Clinical News | December 2019
The two commercially available chimeric antigen receptor (CAR) T-cell products both target cells expressing the CD19 antigen, which is present on malignant and nonmalignant B cells, introducing the possibility that a patient’s humoral immunity may be depleted after treatment. Little is known about the long-term effects of this treatment on patients’ immunity, but a new study provides reassurance that pathogen-specific antibodies and pre-existing humoral immunity are preserved in CAR T-cell–treated adults with B-cell malignancies. This immunity is preserved even in patients who had a complete response (CR) and B cell aplasia.
HHV-6 Foundation | December 2019
Joshua Hill, MD and colleagues from the Fred Hutchinson Cancer Research Center in Seattle found inherited chromosomally-integrated HHV-6 (iciHHV-6) to be associated with increased levels of inflammatory cytokines and an earlier onset of acute graft-versus-host disease (aGVDH) in transplant patients.
HHV-6 Foundation | October 2019
Human herpesvirus 6B in lung fluid of bone marrow transplant recipients with pneumonia is associated with a 2-fold increased risk of death. Importantly, HHV-6B positive patients who were treated with an antiviral had a 60% lower risk of death.
Hutch News | Sabin Russell | June 17, 2019
Infections in immune-compromised patients: 5 new frontiers.
Infectious disease experts gather in Seattle to find solutions for patients with compromised immunity.
The Onco’Zine Brief on PRX | Mar 3, 2018
In this interview, Dr. Hill discusses the promise and perils of CD19-targeted CAR-T cell therapy.
Hutch News | Mary Engel | June 6, 2018
Award will help fund 'paradigm shift' in diagnosing post-transplant infections.
Hutch News | Susan Keown | Nov. 6, 2017
"Benchmark" research could help reduce complications of emerging immunotherapy
HHV-6 Foundation website | Jan. 15, 2016
Dr. Hill is recognized for his work on projects including the use of a reverse transcription PCR test to identify HHV-6 infections in pulmonary disease and pneumonia after transplantation.
HHV-6 Foundation website | June 30, 2015
The K23 grant from the National Institute of Allergy and Infectious Diseases will support Dr. Hill's committed efforts to advance understanding of diseases associated with HHV-6 in hematopoietic cell transplant recipients.
HHV-6 Foundation website | Sep. 30, 2014
Drs. Boeckh and Hill discuss important considerations for treatment of transplant patients.